This activity includes audio. Please ensure your device audio is enabled and the volume is turned up.
Get Started
Podium to Practice: ATTR-CM in Women
What ACC.26 Means for Your Practice
Identify | Diagnose | Treat
The women with ATTR-CM who may be missed in clinical practice
Start
CME Information
Part 1 of a 4-part Congress Series
- Bulleted list
- Bulleted list
Translating congress updates into clinical practice.
ATTR-CM in Women
ACC.26 Congress Coverage
June 2026
p.Val142IleVariant
ESC Heart Failure 2026
Nov 2026
ATTR-CM & Arrhythmia
ESC Congress 2026 & HFSA 2026
Feb 2027
Year in Review Capstone
AHA Scientific Sessions 2026 & ISA 2026
Subtitle
This educational activity is supported by an independent educational grant from BridgeBio Pharma, Inc.
Part 1 of a 4-part Congress Series
Translating congress updates into clinical practice.
ATTR-CM in Women
ACC.26 Congress Coverage
ATTR-CM in Women
ACC.26 Congress Coverage
Nov 2026
ATTR-CM & Arrhythmia
ESC Congress 2026 & HFSA 2026
Feb 2027
Year in Review Capstone
AHA Scientific Sessions 2026 & ISA 2026
Meet today's Faculty, Pooja Prasad, MD
Assistant Clinical Professor Advanced Heart Failure & Transplant Cardiology | Pulmonary Hypertension
University of California, San Francisco
San Francisco, CA Nothing to disclose
Program Overview
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
ACC.26 ATTR-CM: At a Glance
Griffin JM et al. ACC.26 Poster 1379-169 "Association Between Early Increase in sTTR with Acoramidis and Long-Term Effects on Heart Failure-Related Health Status in ATTR-CM" | Waldron J et al. ACC.26 Poster "Treatment Patterns and Preferences in ATTR-CM in the United States: Results from a Real-World Survey" | Ozbey O et al. ACC.26 Abstract 26-A-14031 "Sex-Specific Phenotype Analysis in ATTR-CM" | Soman P et al. ACC.26 Late-Breaking Oral "Long-Term Efficacy and Safety of Acoramidis: 54-Month Open-Label Extension Results" | Fontana M et al. NEJM 2025;392:33-44 + HELIOS-B 48-mo OLE + CMR data (AHA 2025) | Maurer MS et al. NEJM 2018;379:1007-1016 + ATTR-ACT 60-mo OLE & ACC.26 octogenarian RWD | ACC.26 Conference Abstracts, New Orleans, March 28-30, 2026
ACC.26 ATTR-CM: At a Glance
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
Griffin JM et al. ACC.26 Poster 1379-169 "Association Between Early Increase in sTTR with Acoramidis and Long-Term Effects on Heart Failure-Related Health Status in ATTR-CM" | Waldron J et al. ACC.26 Poster "Treatment Patterns and Preferences in ATTR-CM in the United States: Results from a Real-World Survey" | Ozbey O et al. ACC.26 Abstract 26-A-14031 "Sex-Specific Phenotype Analysis in ATTR-CM" | Soman P et al. ACC.26 Late-Breaking Oral "Long-Term Efficacy and Safety of Acoramidis: 54-Month Open-Label Extension Results" | Fontana M et al. NEJM 2025;392:33-44 + HELIOS-B 48-mo OLE + CMR data (AHA 2025) | Maurer MS et al. NEJM 2018;379:1007-1016 + ATTR-ACT 60-mo OLE & ACC.26 octogenarian RWD | ACC.26 Conference Abstracts, New Orleans, March 28-30, 2026
ACC.26 ATTR-CM: At a Glance
ACC.26 ATTR-CM: At a Glance
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
Griffin JM et al. ACC.26 Poster 1379-169 "Association Between Early Increase in sTTR with Acoramidis and Long-Term Effects on Heart Failure-Related Health Status in ATTR-CM" | Waldron J et al. ACC.26 Poster "Treatment Patterns and Preferences in ATTR-CM in the United States: Results from a Real-World Survey" | Ozbey O et al. ACC.26 Abstract 26-A-14031 "Sex-Specific Phenotype Analysis in ATTR-CM" | Soman P et al. ACC.26 Late-Breaking Oral "Long-Term Efficacy and Safety of Acoramidis: 54-Month Open-Label Extension Results" | Fontana M et al. NEJM 2025;392:33-44 + HELIOS-B 48-mo OLE + CMR data (AHA 2025) | Maurer MS et al. NEJM 2018;379:1007-1016 + ATTR-ACT 60-mo OLE & ACC.26 octogenarian RWD | ACC.26 Conference Abstracts, New Orleans, March 28-30, 2026
ACC.26 ATTR-CM: At a Glance
ACC.26 ATTR-CM: At a Glance
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
Continuous
Continuous
Time Since Randomization (months)
Time Since Randomization (months)
Time Since Randomization (months)
Time Since Randomization (months)
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
Griffin JM et al. ACC.26 Poster 1379-169 "Association Between Early Increase in sTTR with Acoramidis and Long-Term Effects on Heart Failure-Related Health Status in ATTR-CM" | Waldron J et al. ACC.26 Poster "Treatment Patterns and Preferences in ATTR-CM in the United States: Results from a Real-World Survey" | Ozbey O et al. ACC.26 Abstract 26-A-14031 "Sex-Specific Phenotype Analysis in ATTR-CM" | Soman P et al. ACC.26 Late-Breaking Oral "Long-Term Efficacy and Safety of Acoramidis: 54-Month Open-Label Extension Results" | Fontana M et al. NEJM 2025;392:33-44 + HELIOS-B 48-mo OLE + CMR data (AHA 2025) | Maurer MS et al. NEJM 2018;379:1007-1016 + ATTR-ACT 60-mo OLE & ACC.26 octogenarian RWD | ACC.26 Conference Abstracts, New Orleans, March 28-30, 2026
ACC.26 ATTR-CM: At a Glance
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
Continuous
Continuous
Time Since Randomization (months)
Time Since Randomization (months)
Griffin JM et al. ACC.26 Poster 1379-169 "Association Between Early Increase in sTTR with Acoramidis and Long-Term Effects on Heart Failure-Related Health Status in ATTR-CM" | Waldron J et al. ACC.26 Poster "Treatment Patterns and Preferences in ATTR-CM in the United States: Results from a Real-World Survey" | Ozbey O et al. ACC.26 Abstract 26-A-14031 "Sex-Specific Phenotype Analysis in ATTR-CM" | Soman P et al. ACC.26 Late-Breaking Oral "Long-Term Efficacy and Safety of Acoramidis: 54-Month Open-Label Extension Results" | Fontana M et al. NEJM 2025;392:33-44 + HELIOS-B 48-mo OLE + CMR data (AHA 2025) | Maurer MS et al. NEJM 2018;379:1007-1016 + ATTR-ACT 60-mo OLE & ACC.26 octogenarian RWD | ACC.26 Conference Abstracts, New Orleans, March 28-30, 2026
Griffin JM et al. ACC.26 Poster 1379-169 "Association Between Early Increase in sTTR with Acoramidis and Long-Term Effects on Heart Failure-Related Health Status in ATTR-CM" | Waldron J et al. ACC.26 Poster "Treatment Patterns and Preferences in ATTR-CM in the United States: Results from a Real-World Survey" | Ozbey O et al. ACC.26 Abstract 26-A-14031 "Sex-Specific Phenotype Analysis in ATTR-CM" | Soman P et al. ACC.26 Late-Breaking Oral "Long-Term Efficacy and Safety of Acoramidis: 54-Month Open-Label Extension Results" | Fontana M et al. NEJM 2025;392:33-44 + HELIOS-B 48-mo OLE + CMR data (AHA 2025) | Maurer MS et al. NEJM 2018;379:1007-1016 + ATTR-ACT 60-mo OLE & ACC.26 octogenarian RWD | ACC.26 Conference Abstracts, New Orleans, March 28-30, 2026
ACC.26 ATTR-CM: At a Glance
ACC.26 ATTR-CM: At a Glance
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
Time Since Randomization (months)
Griffin JM et al. ACC.26 Poster 1379-169 "Association Between Early Increase in sTTR with Acoramidis and Long-Term Effects on Heart Failure-Related Health Status in ATTR-CM" | Waldron J et al. ACC.26 Poster "Treatment Patterns and Preferences in ATTR-CM in the United States: Results from a Real-World Survey" | Ozbey O et al. ACC.26 Abstract 26-A-14031 "Sex-Specific Phenotype Analysis in ATTR-CM" | Soman P et al. ACC.26 Late-Breaking Oral "Long-Term Efficacy and Safety of Acoramidis: 54-Month Open-Label Extension Results" | Fontana M et al. NEJM 2025;392:33-44 + HELIOS-B 48-mo OLE + CMR data (AHA 2025) | Maurer MS et al. NEJM 2018;379:1007-1016 + ATTR-ACT 60-mo OLE & ACC.26 octogenarian RWD | ACC.26 Conference Abstracts, New Orleans, March 28-30, 2026
Griffin JM et al. ACC.26 Poster 1379-169 "Association Between Early Increase in sTTR with Acoramidis and Long-Term Effects on Heart Failure-Related Health Status in ATTR-CM" | Waldron J et al. ACC.26 Poster "Treatment Patterns and Preferences in ATTR-CM in the United States: Results from a Real-World Survey" | Ozbey O et al. ACC.26 Abstract 26-A-14031 "Sex-Specific Phenotype Analysis in ATTR-CM" | Soman P et al. ACC.26 Late-Breaking Oral "Long-Term Efficacy and Safety of Acoramidis: 54-Month Open-Label Extension Results" | Fontana M et al. NEJM 2025;392:33-44 + HELIOS-B 48-mo OLE + CMR data (AHA 2025) | Maurer MS et al. NEJM 2018;379:1007-1016 + ATTR-ACT 60-mo OLE & ACC.26 octogenarian RWD | ACC.26 Conference Abstracts, New Orleans, March 28-30, 2026
Clinical Challenge
ACC.26 ATTR-CM: At a Glance
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
Continuous
Continuous
Time Since Randomization (months)
Time Since Randomization (months)
Time Since Randomization (months)
Griffin JM et al. ACC.26 Poster 1379-169 "Association Between Early Increase in sTTR with Acoramidis and Long-Term Effects on Heart Failure-Related Health Status in ATTR-CM" | Waldron J et al. ACC.26 Poster "Treatment Patterns and Preferences in ATTR-CM in the United States: Results from a Real-World Survey" | Ozbey O et al. ACC.26 Abstract 26-A-14031 "Sex-Specific Phenotype Analysis in ATTR-CM" | Soman P et al. ACC.26 Late-Breaking Oral "Long-Term Efficacy and Safety of Acoramidis: 54-Month Open-Label Extension Results" | Fontana M et al. NEJM 2025;392:33-44 + HELIOS-B 48-mo OLE + CMR data (AHA 2025) | Maurer MS et al. NEJM 2018;379:1007-1016 + ATTR-ACT 60-mo OLE & ACC.26 octogenarian RWD | ACC.26 Conference Abstracts, New Orleans, March 28-30, 2026
ACC.26 ATTR-CM: At a Glance
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
Continuous
Continuous
Time Since Randomization (months)
Time Since Randomization (months)
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
Griffin JM et al. ACC.26 Poster 1379-169 "Association Between Early Increase in sTTR with Acoramidis and Long-Term Effects on Heart Failure-Related Health Status in ATTR-CM" | Waldron J et al. ACC.26 Poster "Treatment Patterns and Preferences in ATTR-CM in the United States: Results from a Real-World Survey" | Ozbey O et al. ACC.26 Abstract 26-A-14031 "Sex-Specific Phenotype Analysis in ATTR-CM" | Soman P et al. ACC.26 Late-Breaking Oral "Long-Term Efficacy and Safety of Acoramidis: 54-Month Open-Label Extension Results" | Fontana M et al. NEJM 2025;392:33-44 + HELIOS-B 48-mo OLE + CMR data (AHA 2025) | Maurer MS et al. NEJM 2018;379:1007-1016 + ATTR-ACT 60-mo OLE & ACC.26 octogenarian RWD | ACC.26 Conference Abstracts, New Orleans, March 28-30, 2026
ACC.26 ATTR-CM: At a Glance
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
Time Since Randomization (months)
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
Griffin JM et al. ACC.26 Poster 1379-169 "Association Between Early Increase in sTTR with Acoramidis and Long-Term Effects on Heart Failure-Related Health Status in ATTR-CM" | Waldron J et al. ACC.26 Poster "Treatment Patterns and Preferences in ATTR-CM in the United States: Results from a Real-World Survey" | Ozbey O et al. ACC.26 Abstract 26-A-14031 "Sex-Specific Phenotype Analysis in ATTR-CM" | Soman P et al. ACC.26 Late-Breaking Oral "Long-Term Efficacy and Safety of Acoramidis: 54-Month Open-Label Extension Results" | Fontana M et al. NEJM 2025;392:33-44 + HELIOS-B 48-mo OLE + CMR data (AHA 2025) | Maurer MS et al. NEJM 2018;379:1007-1016 + ATTR-ACT 60-mo OLE & ACC.26 octogenarian RWD | ACC.26 Conference Abstracts, New Orleans, March 28-30, 2026
ACC.26 ATTR-CM: At a Glance
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
Continuous
Continuous
Time Since Randomization (months)
Time Since Randomization (months)
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
Griffin JM et al. ACC.26 Poster 1379-169 "Association Between Early Increase in sTTR with Acoramidis and Long-Term Effects on Heart Failure-Related Health Status in ATTR-CM" | Waldron J et al. ACC.26 Poster "Treatment Patterns and Preferences in ATTR-CM in the United States: Results from a Real-World Survey" | Ozbey O et al. ACC.26 Abstract 26-A-14031 "Sex-Specific Phenotype Analysis in ATTR-CM" | Soman P et al. ACC.26 Late-Breaking Oral "Long-Term Efficacy and Safety of Acoramidis: 54-Month Open-Label Extension Results" | Fontana M et al. NEJM 2025;392:33-44 + HELIOS-B 48-mo OLE + CMR data (AHA 2025) | Maurer MS et al. NEJM 2018;379:1007-1016 + ATTR-ACT 60-mo OLE & ACC.26 octogenarian RWD | ACC.26 Conference Abstracts, New Orleans, March 28-30, 2026
Clinical Challenge
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
ACC.26 ATTR-CM: At a Glance
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
Time Since Randomization (months)
Time Since Randomization (months)
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
Griffin JM et al. ACC.26 Poster 1379-169 "Association Between Early Increase in sTTR with Acoramidis and Long-Term Effects on Heart Failure-Related Health Status in ATTR-CM" | Waldron J et al. ACC.26 Poster "Treatment Patterns and Preferences in ATTR-CM in the United States: Results from a Real-World Survey" | Ozbey O et al. ACC.26 Abstract 26-A-14031 "Sex-Specific Phenotype Analysis in ATTR-CM" | Soman P et al. ACC.26 Late-Breaking Oral "Long-Term Efficacy and Safety of Acoramidis: 54-Month Open-Label Extension Results" | Fontana M et al. NEJM 2025;392:33-44 + HELIOS-B 48-mo OLE + CMR data (AHA 2025) | Maurer MS et al. NEJM 2018;379:1007-1016 + ATTR-ACT 60-mo OLE & ACC.26 octogenarian RWD | ACC.26 Conference Abstracts, New Orleans, March 28-30, 2026
Clinical Challenge
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
Diagnosis confirmed: ATTR-CM
Grade 2–3 PYP uptake
Grade 2–3 PYP uptake
Grade 2–3 PYP uptake
Grade 2–3 PYP uptake
Grade 2–3 PYP uptake
Grade 2–3 PYP uptake
Grade 2–3 PYP uptake
Grade 2–3 PYP uptake
Grade 2–3 PYP uptake
Grade 2–3 PYP uptake
Grade 2–3 PYP uptake
Grade 2–3 PYP uptake
Grade 2–3 PYP uptake
Grade 2–3 PYP uptake
Natural history: Gonzalez-Lopez E et al. PMC9700255. Disease staging: Gillmore JD et al. ESC Heart Failure 2020 (PMC7755026). Earlier diagnosis: Circulation Heart Failure 2024. CV hospitalisation: Antonopoulos AS et al. ESC Heart Failure 2026 (meta-analysis, n=5,203). Individual product labelling should be consulted.
Diagnosis confirmed: ATTR-CM
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
Clinical Challenge
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
Real-world effectiveness
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
Subtitle
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
Subtitle
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
Subtitle
Natural history: Gonzalez-Lopez E et al. PMC9700255. Disease staging: Gillmore JD et al. ESC Heart Failure 2020 (PMC7755026). Earlier diagnosis: Circulation Heart Failure 2024. CV hospitalisation: Antonopoulos AS et al. ESC Heart Failure 2026 (meta-analysis, n=5,203). Individual product labelling should be consulted.
Clinical Challenge
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
Thank You
Apply these insights in your next patient evaluation.
Claim CME Credit
ESC-HF 2026 ATTR-CM
Iridium CE
Created on June 17, 2026
Explore the latest evidence in hereditary ATTR-CM through expert faculty insights, interactive knowledge checks, and an AI-guided patient case. Strengthen diagnostic, genetic screening, and treatment decision-making using emerging ESC Heart Failure 2026 data.
Start designing with a free template
Discover more than 1500 professional designs like these:
View
Microcourse: Team Cybersecurity
View
Microcourse: Learn Spanish
View
Microcourse: Key Skills for University
View
Professional quiz mobile
View
Microlearning: How to Study Better
View
Microcourse: Artificial Intelligence in Education
View
How to Create the Perfect Final Project
Explore all templates
Transcript
This activity includes audio. Please ensure your device audio is enabled and the volume is turned up.
Get Started
Podium to Practice: ATTR-CM in Women
What ACC.26 Means for Your Practice
Identify | Diagnose | Treat
The women with ATTR-CM who may be missed in clinical practice
Start
CME Information
Part 1 of a 4-part Congress Series
Translating congress updates into clinical practice.
ATTR-CM in Women
ACC.26 Congress Coverage
June 2026
p.Val142IleVariant
ESC Heart Failure 2026
Nov 2026
ATTR-CM & Arrhythmia
ESC Congress 2026 & HFSA 2026
Feb 2027
Year in Review Capstone
AHA Scientific Sessions 2026 & ISA 2026
Subtitle
This educational activity is supported by an independent educational grant from BridgeBio Pharma, Inc.
Part 1 of a 4-part Congress Series
Translating congress updates into clinical practice.
ATTR-CM in Women
ACC.26 Congress Coverage
ATTR-CM in Women
ACC.26 Congress Coverage
Nov 2026
ATTR-CM & Arrhythmia
ESC Congress 2026 & HFSA 2026
Feb 2027
Year in Review Capstone
AHA Scientific Sessions 2026 & ISA 2026
Meet today's Faculty, Pooja Prasad, MD
Assistant Clinical Professor Advanced Heart Failure & Transplant Cardiology | Pulmonary Hypertension University of California, San Francisco San Francisco, CA Nothing to disclose
Program Overview
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
ACC.26 ATTR-CM: At a Glance
Griffin JM et al. ACC.26 Poster 1379-169 "Association Between Early Increase in sTTR with Acoramidis and Long-Term Effects on Heart Failure-Related Health Status in ATTR-CM" | Waldron J et al. ACC.26 Poster "Treatment Patterns and Preferences in ATTR-CM in the United States: Results from a Real-World Survey" | Ozbey O et al. ACC.26 Abstract 26-A-14031 "Sex-Specific Phenotype Analysis in ATTR-CM" | Soman P et al. ACC.26 Late-Breaking Oral "Long-Term Efficacy and Safety of Acoramidis: 54-Month Open-Label Extension Results" | Fontana M et al. NEJM 2025;392:33-44 + HELIOS-B 48-mo OLE + CMR data (AHA 2025) | Maurer MS et al. NEJM 2018;379:1007-1016 + ATTR-ACT 60-mo OLE & ACC.26 octogenarian RWD | ACC.26 Conference Abstracts, New Orleans, March 28-30, 2026
ACC.26 ATTR-CM: At a Glance
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
Griffin JM et al. ACC.26 Poster 1379-169 "Association Between Early Increase in sTTR with Acoramidis and Long-Term Effects on Heart Failure-Related Health Status in ATTR-CM" | Waldron J et al. ACC.26 Poster "Treatment Patterns and Preferences in ATTR-CM in the United States: Results from a Real-World Survey" | Ozbey O et al. ACC.26 Abstract 26-A-14031 "Sex-Specific Phenotype Analysis in ATTR-CM" | Soman P et al. ACC.26 Late-Breaking Oral "Long-Term Efficacy and Safety of Acoramidis: 54-Month Open-Label Extension Results" | Fontana M et al. NEJM 2025;392:33-44 + HELIOS-B 48-mo OLE + CMR data (AHA 2025) | Maurer MS et al. NEJM 2018;379:1007-1016 + ATTR-ACT 60-mo OLE & ACC.26 octogenarian RWD | ACC.26 Conference Abstracts, New Orleans, March 28-30, 2026
ACC.26 ATTR-CM: At a Glance
ACC.26 ATTR-CM: At a Glance
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
Griffin JM et al. ACC.26 Poster 1379-169 "Association Between Early Increase in sTTR with Acoramidis and Long-Term Effects on Heart Failure-Related Health Status in ATTR-CM" | Waldron J et al. ACC.26 Poster "Treatment Patterns and Preferences in ATTR-CM in the United States: Results from a Real-World Survey" | Ozbey O et al. ACC.26 Abstract 26-A-14031 "Sex-Specific Phenotype Analysis in ATTR-CM" | Soman P et al. ACC.26 Late-Breaking Oral "Long-Term Efficacy and Safety of Acoramidis: 54-Month Open-Label Extension Results" | Fontana M et al. NEJM 2025;392:33-44 + HELIOS-B 48-mo OLE + CMR data (AHA 2025) | Maurer MS et al. NEJM 2018;379:1007-1016 + ATTR-ACT 60-mo OLE & ACC.26 octogenarian RWD | ACC.26 Conference Abstracts, New Orleans, March 28-30, 2026
ACC.26 ATTR-CM: At a Glance
ACC.26 ATTR-CM: At a Glance
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
Continuous
Continuous
Time Since Randomization (months)
Time Since Randomization (months)
Time Since Randomization (months)
Time Since Randomization (months)
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
Griffin JM et al. ACC.26 Poster 1379-169 "Association Between Early Increase in sTTR with Acoramidis and Long-Term Effects on Heart Failure-Related Health Status in ATTR-CM" | Waldron J et al. ACC.26 Poster "Treatment Patterns and Preferences in ATTR-CM in the United States: Results from a Real-World Survey" | Ozbey O et al. ACC.26 Abstract 26-A-14031 "Sex-Specific Phenotype Analysis in ATTR-CM" | Soman P et al. ACC.26 Late-Breaking Oral "Long-Term Efficacy and Safety of Acoramidis: 54-Month Open-Label Extension Results" | Fontana M et al. NEJM 2025;392:33-44 + HELIOS-B 48-mo OLE + CMR data (AHA 2025) | Maurer MS et al. NEJM 2018;379:1007-1016 + ATTR-ACT 60-mo OLE & ACC.26 octogenarian RWD | ACC.26 Conference Abstracts, New Orleans, March 28-30, 2026
ACC.26 ATTR-CM: At a Glance
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
Continuous
Continuous
Time Since Randomization (months)
Time Since Randomization (months)
Griffin JM et al. ACC.26 Poster 1379-169 "Association Between Early Increase in sTTR with Acoramidis and Long-Term Effects on Heart Failure-Related Health Status in ATTR-CM" | Waldron J et al. ACC.26 Poster "Treatment Patterns and Preferences in ATTR-CM in the United States: Results from a Real-World Survey" | Ozbey O et al. ACC.26 Abstract 26-A-14031 "Sex-Specific Phenotype Analysis in ATTR-CM" | Soman P et al. ACC.26 Late-Breaking Oral "Long-Term Efficacy and Safety of Acoramidis: 54-Month Open-Label Extension Results" | Fontana M et al. NEJM 2025;392:33-44 + HELIOS-B 48-mo OLE + CMR data (AHA 2025) | Maurer MS et al. NEJM 2018;379:1007-1016 + ATTR-ACT 60-mo OLE & ACC.26 octogenarian RWD | ACC.26 Conference Abstracts, New Orleans, March 28-30, 2026
Griffin JM et al. ACC.26 Poster 1379-169 "Association Between Early Increase in sTTR with Acoramidis and Long-Term Effects on Heart Failure-Related Health Status in ATTR-CM" | Waldron J et al. ACC.26 Poster "Treatment Patterns and Preferences in ATTR-CM in the United States: Results from a Real-World Survey" | Ozbey O et al. ACC.26 Abstract 26-A-14031 "Sex-Specific Phenotype Analysis in ATTR-CM" | Soman P et al. ACC.26 Late-Breaking Oral "Long-Term Efficacy and Safety of Acoramidis: 54-Month Open-Label Extension Results" | Fontana M et al. NEJM 2025;392:33-44 + HELIOS-B 48-mo OLE + CMR data (AHA 2025) | Maurer MS et al. NEJM 2018;379:1007-1016 + ATTR-ACT 60-mo OLE & ACC.26 octogenarian RWD | ACC.26 Conference Abstracts, New Orleans, March 28-30, 2026
ACC.26 ATTR-CM: At a Glance
ACC.26 ATTR-CM: At a Glance
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
Time Since Randomization (months)
Griffin JM et al. ACC.26 Poster 1379-169 "Association Between Early Increase in sTTR with Acoramidis and Long-Term Effects on Heart Failure-Related Health Status in ATTR-CM" | Waldron J et al. ACC.26 Poster "Treatment Patterns and Preferences in ATTR-CM in the United States: Results from a Real-World Survey" | Ozbey O et al. ACC.26 Abstract 26-A-14031 "Sex-Specific Phenotype Analysis in ATTR-CM" | Soman P et al. ACC.26 Late-Breaking Oral "Long-Term Efficacy and Safety of Acoramidis: 54-Month Open-Label Extension Results" | Fontana M et al. NEJM 2025;392:33-44 + HELIOS-B 48-mo OLE + CMR data (AHA 2025) | Maurer MS et al. NEJM 2018;379:1007-1016 + ATTR-ACT 60-mo OLE & ACC.26 octogenarian RWD | ACC.26 Conference Abstracts, New Orleans, March 28-30, 2026
Griffin JM et al. ACC.26 Poster 1379-169 "Association Between Early Increase in sTTR with Acoramidis and Long-Term Effects on Heart Failure-Related Health Status in ATTR-CM" | Waldron J et al. ACC.26 Poster "Treatment Patterns and Preferences in ATTR-CM in the United States: Results from a Real-World Survey" | Ozbey O et al. ACC.26 Abstract 26-A-14031 "Sex-Specific Phenotype Analysis in ATTR-CM" | Soman P et al. ACC.26 Late-Breaking Oral "Long-Term Efficacy and Safety of Acoramidis: 54-Month Open-Label Extension Results" | Fontana M et al. NEJM 2025;392:33-44 + HELIOS-B 48-mo OLE + CMR data (AHA 2025) | Maurer MS et al. NEJM 2018;379:1007-1016 + ATTR-ACT 60-mo OLE & ACC.26 octogenarian RWD | ACC.26 Conference Abstracts, New Orleans, March 28-30, 2026
Clinical Challenge
ACC.26 ATTR-CM: At a Glance
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
Continuous
Continuous
Time Since Randomization (months)
Time Since Randomization (months)
Time Since Randomization (months)
Griffin JM et al. ACC.26 Poster 1379-169 "Association Between Early Increase in sTTR with Acoramidis and Long-Term Effects on Heart Failure-Related Health Status in ATTR-CM" | Waldron J et al. ACC.26 Poster "Treatment Patterns and Preferences in ATTR-CM in the United States: Results from a Real-World Survey" | Ozbey O et al. ACC.26 Abstract 26-A-14031 "Sex-Specific Phenotype Analysis in ATTR-CM" | Soman P et al. ACC.26 Late-Breaking Oral "Long-Term Efficacy and Safety of Acoramidis: 54-Month Open-Label Extension Results" | Fontana M et al. NEJM 2025;392:33-44 + HELIOS-B 48-mo OLE + CMR data (AHA 2025) | Maurer MS et al. NEJM 2018;379:1007-1016 + ATTR-ACT 60-mo OLE & ACC.26 octogenarian RWD | ACC.26 Conference Abstracts, New Orleans, March 28-30, 2026
ACC.26 ATTR-CM: At a Glance
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
Continuous
Continuous
Time Since Randomization (months)
Time Since Randomization (months)
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
Griffin JM et al. ACC.26 Poster 1379-169 "Association Between Early Increase in sTTR with Acoramidis and Long-Term Effects on Heart Failure-Related Health Status in ATTR-CM" | Waldron J et al. ACC.26 Poster "Treatment Patterns and Preferences in ATTR-CM in the United States: Results from a Real-World Survey" | Ozbey O et al. ACC.26 Abstract 26-A-14031 "Sex-Specific Phenotype Analysis in ATTR-CM" | Soman P et al. ACC.26 Late-Breaking Oral "Long-Term Efficacy and Safety of Acoramidis: 54-Month Open-Label Extension Results" | Fontana M et al. NEJM 2025;392:33-44 + HELIOS-B 48-mo OLE + CMR data (AHA 2025) | Maurer MS et al. NEJM 2018;379:1007-1016 + ATTR-ACT 60-mo OLE & ACC.26 octogenarian RWD | ACC.26 Conference Abstracts, New Orleans, March 28-30, 2026
ACC.26 ATTR-CM: At a Glance
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
Time Since Randomization (months)
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
Griffin JM et al. ACC.26 Poster 1379-169 "Association Between Early Increase in sTTR with Acoramidis and Long-Term Effects on Heart Failure-Related Health Status in ATTR-CM" | Waldron J et al. ACC.26 Poster "Treatment Patterns and Preferences in ATTR-CM in the United States: Results from a Real-World Survey" | Ozbey O et al. ACC.26 Abstract 26-A-14031 "Sex-Specific Phenotype Analysis in ATTR-CM" | Soman P et al. ACC.26 Late-Breaking Oral "Long-Term Efficacy and Safety of Acoramidis: 54-Month Open-Label Extension Results" | Fontana M et al. NEJM 2025;392:33-44 + HELIOS-B 48-mo OLE + CMR data (AHA 2025) | Maurer MS et al. NEJM 2018;379:1007-1016 + ATTR-ACT 60-mo OLE & ACC.26 octogenarian RWD | ACC.26 Conference Abstracts, New Orleans, March 28-30, 2026
ACC.26 ATTR-CM: At a Glance
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
Continuous
Continuous
Time Since Randomization (months)
Time Since Randomization (months)
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
Griffin JM et al. ACC.26 Poster 1379-169 "Association Between Early Increase in sTTR with Acoramidis and Long-Term Effects on Heart Failure-Related Health Status in ATTR-CM" | Waldron J et al. ACC.26 Poster "Treatment Patterns and Preferences in ATTR-CM in the United States: Results from a Real-World Survey" | Ozbey O et al. ACC.26 Abstract 26-A-14031 "Sex-Specific Phenotype Analysis in ATTR-CM" | Soman P et al. ACC.26 Late-Breaking Oral "Long-Term Efficacy and Safety of Acoramidis: 54-Month Open-Label Extension Results" | Fontana M et al. NEJM 2025;392:33-44 + HELIOS-B 48-mo OLE + CMR data (AHA 2025) | Maurer MS et al. NEJM 2018;379:1007-1016 + ATTR-ACT 60-mo OLE & ACC.26 octogenarian RWD | ACC.26 Conference Abstracts, New Orleans, March 28-30, 2026
Clinical Challenge
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
ACC.26 ATTR-CM: At a Glance
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
Time Since Randomization (months)
Time Since Randomization (months)
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
Griffin JM et al. ACC.26 Poster 1379-169 "Association Between Early Increase in sTTR with Acoramidis and Long-Term Effects on Heart Failure-Related Health Status in ATTR-CM" | Waldron J et al. ACC.26 Poster "Treatment Patterns and Preferences in ATTR-CM in the United States: Results from a Real-World Survey" | Ozbey O et al. ACC.26 Abstract 26-A-14031 "Sex-Specific Phenotype Analysis in ATTR-CM" | Soman P et al. ACC.26 Late-Breaking Oral "Long-Term Efficacy and Safety of Acoramidis: 54-Month Open-Label Extension Results" | Fontana M et al. NEJM 2025;392:33-44 + HELIOS-B 48-mo OLE + CMR data (AHA 2025) | Maurer MS et al. NEJM 2018;379:1007-1016 + ATTR-ACT 60-mo OLE & ACC.26 octogenarian RWD | ACC.26 Conference Abstracts, New Orleans, March 28-30, 2026
Clinical Challenge
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
Diagnosis confirmed: ATTR-CM
Grade 2–3 PYP uptake
Grade 2–3 PYP uptake
Grade 2–3 PYP uptake
Grade 2–3 PYP uptake
Grade 2–3 PYP uptake
Grade 2–3 PYP uptake
Grade 2–3 PYP uptake
Grade 2–3 PYP uptake
Grade 2–3 PYP uptake
Grade 2–3 PYP uptake
Grade 2–3 PYP uptake
Grade 2–3 PYP uptake
Grade 2–3 PYP uptake
Grade 2–3 PYP uptake
Natural history: Gonzalez-Lopez E et al. PMC9700255. Disease staging: Gillmore JD et al. ESC Heart Failure 2020 (PMC7755026). Earlier diagnosis: Circulation Heart Failure 2024. CV hospitalisation: Antonopoulos AS et al. ESC Heart Failure 2026 (meta-analysis, n=5,203). Individual product labelling should be consulted.
Diagnosis confirmed: ATTR-CM
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
Clinical Challenge
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
Real-world effectiveness
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
Subtitle
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
Subtitle
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
Subtitle
Natural history: Gonzalez-Lopez E et al. PMC9700255. Disease staging: Gillmore JD et al. ESC Heart Failure 2020 (PMC7755026). Earlier diagnosis: Circulation Heart Failure 2024. CV hospitalisation: Antonopoulos AS et al. ESC Heart Failure 2026 (meta-analysis, n=5,203). Individual product labelling should be consulted.
Clinical Challenge
This paragraph is ready to be filled with incredible creativity, experiences, and stories.
Thank You
Apply these insights in your next patient evaluation.
Claim CME Credit